Key result
RBM3 is a cold shock RNA-binding protein that regulates skeletal muscle mass and represents a potential therapeutic target to prevent muscle atrophy and promote hypertrophy.
The cold shock RNA-binding protein RBM3 represents a potential therapeutic target to prevent skeletal muscle atrophy during disuse or pathological conditions.
Answers are grounded in this paper and cite their sources.
RBM3 may offer a novel target against muscle atrophy; leaves open whether modulation improves outcomes in orthopedic or aging populations.
Muscle atrophy is among the most common conditions during sickness, injury, aging and after orthopedic surgeries, and is associated with poor health outcomes. As such, it is important to understand the molecular machinery responsible for the control of muscle mass and function for development of therapeutic targets and strategies to combat muscle atrophy. We have identified the cold shock RNA binding protein, RNA-binding motif protein 3 (RBM3) as a critical regulatory node in the control of skeletal muscle mass and herein, we review our current knowledge of its actions in skeletal muscle. We also cover future directions of research and how this knowledge may translate into therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Pelt et al. (2020) conducted a review in Skeletal muscle atrophy. RBM3 (Cold shock RNA-binding protein) was evaluated. RBM3 is a cold shock RNA-binding protein that regulates skeletal muscle mass and represents a potential therapeutic target to prevent muscle atrophy and promote hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: